Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	SEK 10.00	0.00%	3,652
23/07/26	SEK 10.00	0.00%	5
22/07/26	SEK 10.00	-0.99%	2,754
20/07/26	SEK 10.10	-2.88%	1,209
17/07/26	SEK 10.40	+2.97%	1,004

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 24/07/2026 BST			5-day change	1st Jan Change
10.00 ^SEK	0.00%		-3.85%	-41.00%

05-19	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
05-19	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	189M 19.48M 17.11M 15.91M 14.6M 27.43M 1.88B 27.85M 73.81M 922M 73.12M 71.55M 3.19B	P/E 2024	-33.7x	P/E 2025	-36.6x
Enterprise Value	168M 17.35M 15.24M 14.17M 13.01M 24.44M 1.67B 24.81M 65.75M 821M 65.14M 63.73M 2.84B	EV / Sales 2024	7.85x	EV / Sales 2025	5.87x
Free-Float	14.76%	Yield 2024 *	-	Yield 2025	-

05-19	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
05-19	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Promimic nomination committee proposes new chairman	RE
02-24	Promimic Q4 net sales SEK 11.5 mln	RE
02-24	Promimic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
11-19	Promimic Q3 sales of SEK 12.9 mln	RE
11-19	Promimic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/08/25	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/06/25	Promimic's CFO Heidi Bader makes a minor share purchase	FW
15/05/25	Promimic reports slightly lower operating loss	FW
15/05/25	Promimic Q1 Sales Increase 1.4% To 8.8 Msek	RE
15/05/25	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
05/05/25	Promimic deepens collaboration with Curiteva	FW

1 week	-3.85%
1 month	-2.91%
3 months	-7.41%
6 months	-33.11%
Current year	-41.00%

Promimic AB Share Price

Stocks

PRO

SE0017487242

Biotechnology & Medical Research

Valuation: Promimic AB

Chart: Promimic AB

Latest news : Promimic AB

Analysts' recommendations: Promimic AB

Press Releases: Promimic AB

Quotes and Performance

Course Extremes

Managers and Directors: Promimic AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	9.6	10.4
1 month	9.6	11.4
Current year	8.14	16.55
1 year	8.14	20.5
3 years	8.14	45
5 years	8.14	45
10 years	8.14	45

Manager	Title	Age	Since
Magnus Larsson CEO	Chief Executive Officer	63	17/01/2017
Per Gunnar Kjellin CTO	Chief Tech/Sci/R&D Officer	54	31/12/2003
Heidi Bader DFI	Director of Finance/CFO	45	31/12/2022

Director	Title	Age	Since
Tommy Karlsson BRD	Director/Board Member	80	31/12/2017
Helena Maria Brisby BRD	Director/Board Member	61	31/12/2020
Pia Renaudin BRD	Director/Board Member	59	31/12/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/10/24	Magnus Larsson	Fiscal year	Chief Executive Officer	16,000	0.0869%
11/10/24	Magnus Larsson	Sell	Chief Executive Officer	125,000	0.6785%
11/10/24	Magnus Larsson	Fiscal year	Chief Executive Officer	160,000	0.8685%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROMIMIC AB	0.00%	-3.85%	-44.60%	-66.33%	19.48M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+10.44%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+634.87%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+65.64%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.16%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+40.92%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.36%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.03%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-33.61%	12.7B
Average	+0.20%	+0.36%	+43.54%	+87.24%	24.53B
Weighted average by Cap.	+0.48%	+0.91%	+74.41%	+136.26%

	2024	2025
Net sales	48.91M 5.04M 4.43M 4.12M 3.78M 7.1M 486M 7.21M 19.11M 239M 18.93M 18.52M 825M	51.06M 5.26M 4.62M 4.3M 3.95M 7.41M 507M 7.53M 19.95M 249M 19.76M 19.34M 862M
Net income	-12.55M -1.29M -1.14M -1.06M -970K -1.82M -125M -1.85M -4.9M -61.26M -4.86M -4.75M -212M	-8.75M -903K -793K -737K -676K -1.27M -86.92M -1.29M -3.42M -42.73M -3.39M -3.32M -148M
Net Debt	-35.76M -3.69M -3.24M -3.01M -2.76M -5.19M -355M -5.27M -13.97M -175M -13.84M -13.54M -604M	-20.63M -2.13M -1.87M -1.74M -1.59M -3M -205M -3.04M -8.06M -101M -7.98M -7.81M -348M